BAP1 and cancer: To exemplify the value of our BAP1 SGE data, we obtained phenotypes from the UK Biobank27 for all BAP1 variant carriers and noncarrier controls, revealing that nonsynonymous BAP1 variants classified as disruptive/depleted by SGE were significantly associated with a cancer diagnosis and, independent of cancer, significantly higher levels of circulating IGF-1.